Skip to main content
SpringerLink
Log in

miR-501 acts as an independent prognostic factor that promotes the epithelial–mesenchymal transition through targeting JDP2 in hepatocellular carcinoma

  • Research Article
  • Published:
Human Cell Aims and scope Submit manuscript

Abstract

Hepatocellular carcinoma (HCC), the second common cancer, was a kind of primary liver cancer with high incidence. miR-501, identified as a novel regulator, was acted as a potential biomarker in several diseases. JDP2, acted as a repressor of AP-1 complex, was a member of the basic leucine zipper (bZIP) transcription factor family. RT-qPCR was applied to evaluate miR-501 and JDP2 expression level and we found that miR-501 was upregulated in HCC tissues and cells. miR-501 ectopic expression promoted HCC cell invasion and epithelial–mesenchymal transition (EMT), while low expression present the opposite results. JDP2 was downregulated in HCC tissues and cells, and overexpressed JDP2 facilitated HCC cell invasion and EMT. Furthermore, luciferase reporter assay indicated that JDP2 was a target of miR-501 and altered miR-501 expression the JPD2 mRNA may changed. The expression of miR-501 and JDP2 had negative connection in HCC tissues. In addition, Kaplan–Meier method revealed that miR-501 upregulation or JDP2 downregulation predicted poor prognosis in HCC patients. miR-501 promoted cell invasion and EMT by regulated JDP2 in hepatocellular carcinoma. The newly identified miR-501/JDP2 axis provides novel insight into the pathogenesis of hepatocellular carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

Availability of data and material

The data sets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.

    Article  PubMed  Google Scholar 

  2. Yang JD, Roberts LR. Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin N Am. 2010;24:899–919 (viii).

    Article  CAS  Google Scholar 

  3. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003;139:817–23.

    Article  PubMed  Google Scholar 

  4. Ye QH, Qin LX, Forgues M, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med. 2003;9:416–23.

    Article  CAS  PubMed  Google Scholar 

  5. Gan W, Huang JL, Zhang MX, et al. New nomogram predicts the recurrence of hepatocellular carcinoma in patients with negative preoperative serum AFP subjected to curative resection. J Surg Oncol. 2018;117(7):1540–7.

    Article  PubMed  Google Scholar 

  6. Ambros V. The functions of animal microRNAs. Nature. 2004;431:350–5.

    Article  CAS  PubMed  Google Scholar 

  7. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.

    Article  CAS  PubMed  Google Scholar 

  8. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. 294. New York: Science; 2001. pp. 853–8.

    Google Scholar 

  9. Mizbani A, Luca E, Rushing EJ, Krutzfeldt J. MicroRNA deep sequencing in two adult stem cell populations identifies miR-501 as a novel regulator of myosin heavy chain during muscle regeneration. Development. 2016;143:4137–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Liu Y, Chai Y, Zhang J, Tang J. A function variant at miR-501 alters susceptibility to hepatocellular carcinoma in a Chinese Han population. Cell Physiol Biochem. 2016; 38:2500–8.

    Article  CAS  PubMed  Google Scholar 

  11. Chen S, Zhou YC, Chen Y, et al. Expression profile of miR-501-5p in lung adenocarcinoma patients from Xuanwei area. Nan Fang Yi Ke Da Xue Xue Bao (J South Med Univ). 2017;37:354–59.

    CAS  Google Scholar 

  12. Hara N, Kikuchi M, Miyashita A, et al. Serum microRNA miR-501-3p as a potential biomarker related to the progression of Alzheimer’s disease. Acta Neuropathol Commun. 2017;5:10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Fan D, Ren B, Yang X, Liu J, Zhang Z. Upregulation of miR-501-5p activates the wnt/beta-catenin signaling pathway and enhances stem cell-like phenotype in gastric cancer. J Exp Clin Cancer Res CR. 2016;35:177.

    Article  CAS  PubMed  Google Scholar 

  14. Sanches JGP, Xu Y, Yabasin IB, et al. miR-501 is upregulated in cervical cancer and promotes cell proliferation, migration and invasion by targeting CYLD. Chemico-biol Interact. 2018;285:85–95.

    Article  CAS  Google Scholar 

  15. Jin C, Li H, Murata T, et al. JDP2, a repressor of AP-1, recruits a histone deacetylase 3 complex to inhibit the retinoic acid-induced differentiation of F9 cells. Mol Cell Biol. 2002;22:4815–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Huang YC, Saito S, Yokoyama KK. Histone chaperone Jun dimerization protein 2 (JDP2): role in cellular senescence and aging. Kaohsiung J Med Sci. 2010;26:515–31.

    Article  CAS  PubMed  Google Scholar 

  17. Katz S, Heinrich R, Aronheim A. The AP-1 repressor, JDP2, is a bona fide substrate for the c-Jun N-terminal kinase. FEBS Lett. 2001;506:196–200.

    Article  CAS  PubMed  Google Scholar 

  18. Heinrich R, Livne E, Ben-Izhak O, Aronheim A. The c-Jun dimerization protein 2 inhibits cell transformation and acts as a tumor suppressor gene. J Biol Chem. 2004;279:5708–15.

    Article  CAS  PubMed  Google Scholar 

  19. van der Weyden L, Rust AG, McIntyre RE, et al. Jdp2 downregulates Trp53 transcription to promote leukaemogenesis in the context of Trp53 heterozygosity. Oncogene. 2013;32:397–402.

    Article  CAS  PubMed  Google Scholar 

  20. Rasmussen MH, Wang B, Wabl M, Nielsen AL, Pedersen FS. Activation of alternative Jdp2 promoters and functional protein isoforms in T-cell lymphomas by retroviral insertion mutagenesis. Nucleic Acids Res. 2009;37:4657–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Xu Y, Liu Z, Guo K. The effect of JDP2 and ATF2 on the epithelial-mesenchymal transition of human pancreatic cancer cell lines. Pathol Oncol Res POR. 2012;18:571–7.

    Article  CAS  PubMed  Google Scholar 

  22. Yuanhong X, Feng X, Qingchang L, Jianpeng F, Zhe L, Kejian G. Downregulation of AP-1 repressor JDP2 is associated with tumor metastasis and poor prognosis in patients with pancreatic carcinoma. Int J Biol Markers. 2010;25:136–40.

    Article  PubMed  Google Scholar 

  23. Liu Z, Du R, Long J, et al. JDP2 inhibits the epithelial-to-mesenchymal transition in pancreatic cancer BxPC3 cells. Tumour Biol. 2012;33:1527–34.

    Article  CAS  PubMed  Google Scholar 

  24. Chen YL, Chan SH, Lin PY, Chu PY. The expression of a tumor suppressor gene JDP2 and its prognostic value in hepatocellular carcinoma patients. Hum Pathol. 2017;63:212–16.

    Article  CAS  PubMed  Google Scholar 

  25. Huang DH, Wang GY, Zhang JW, Li Y, Zeng XC, Jiang N. MiR-501-5p regulates CYLD expression and promotes cell proliferation in human hepatocellular carcinoma. Jpn J Clin Oncol. 2015;45:738–44.

    Article  PubMed  Google Scholar 

  26. Ling Q, Xu X, Ye P, et al. The prognostic relevance of primary tumor location in patients undergoing resection for pancreatic ductal adenocarcinoma. Oncotarget. 2017;8:15159–67.

    PubMed  PubMed Central  Google Scholar 

Download references

Funding

This study was supported by National Natural Science Foundation of China (project no.: 81702783) and The Natural Science Foundation of Guangdong Province (project no.: 2017A030310574).

Author information

Author notes

  1. Chuanzhao Zhang and Zhixiang Jian contributed equally to this study.

Authors and Affiliations

  1. Department of Surgical Oncology, Tungwah Hospital of Sun Yat-Sen University, Dongguan, 523110, Guangdong, China

    Weixuan Yu

  2. Biotherapy Department, Sun Yat-sen Memorial Hospital, Guangzhou, 510120, Guangdong, China

    Wen Deng

  3. Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, China

    Qiang Zhao

  4. Department of General Surgery, Guangdong General Hospital, Guangdong Academy of Medical Sciences, No. 106 Zhongshan Er Road, Guangzhou, 510080, China

    Hongkai Zhuang, Chuanzhao Zhang & Zhixiang Jian

Authors
  1. Weixuan Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wen Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qiang Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hongkai Zhuang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chuanzhao Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zhixiang Jian
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

CZ and ZJ as the co-corresponding author contributed to the conception of the study and contributed significantly to analyses; WY as the first authorship performed the data and wrote the manuscript; WD as the second author contributed to analyses; QZ as the third author helped perform the analysis with constructive discussions; HZ as the fourth author contributed to the manuscript preparation. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Chuanzhao Zhang or Zhixiang Jian.

Ethics declarations

Conflict of interest

All authors declare that they have no financial or other conflicts of interest in relation to this research and its publication.

Ethics approval and consent to participate

Ethics Committee of Guangdong General Hospital approved the research, and written informed consent was given by all participants.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yu, W., Deng, W., Zhao, Q. et al. miR-501 acts as an independent prognostic factor that promotes the epithelial–mesenchymal transition through targeting JDP2 in hepatocellular carcinoma. Human Cell 32, 343–351 (2019). https://doi.org/10.1007/s13577-019-00243-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13577-019-00243-7

Keywords

Search

Navigation